Immuron (IMRN) Non Operating Interest Expenses (2016 - 2024)

Immuron's (IMRN) quarterly Non Operating Interest Expenses came in at -$2629.6 in Q4 2024, up 98.68% quarter-over-quarter from -$198652.0 in Q4 2018.

Immuron (IMRN) Non Operating Interest Expenses (2016 - 2024) Analysis & Trends

Immuron's Non Operating Interest Expenses history runs 4 years deep, the most recent figure standing at -$2629.6 for Q4 2024.

On a quarterly basis, Non Operating Interest Expenses changed N/A year-over-year to -$2629.6 in Q4 2024; TTM through Dec 2024 was -$214157.0, a N/A change from a year earlier, with the FY2022 full-year figure at -$4441.2, changed N/A from the prior year.
Non Operating Interest Expenses rose to -$2629.6 in Q4 2024 per IMRN's latest filing, from -$198652.0 in the prior quarter.
Across five years, Non Operating Interest Expenses topped out at -$2629.6 in Q4 2024 and bottomed at -$2629.6 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non Operating Interest Expenses (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-220,921.81
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	-
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Immuron	255.19 Mn	243.53 Mn	-	-

Download Data